Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.
Jawad Butt, MD, PhD
Advertisement
Jawad Butt, MD, PhD, is a research fellow in the department of cardiology at Copenhagen University Hospital and the University of Glasgow.
Articles by Jawad Butt, MD, PhD
Butt discusses his secondary analysis of the FINEARTS-HF trial, which demonstrated consistent treatment efficacy in patients with and without a history of IHD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
Tips on Optimizing HS Biologics, Combinations, and Surgery
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5